EFdA-P + Progestin Intravaginal Film
A next generation MPT film platform for once a month intravaginal administration of 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) or the EFdA prodrug (EFdA-P) and a progestin (levonorgestrel (LNG) or etonogestrel (ENG)) to achieve the dual goal of preventing HIV infection and pregnancy.
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Topical - Film - Vaginal
Mechanism of Action:
Nucleoside reverse transcriptase translocation inhibitor and progestin hormonal contraceptive
Developer:
- Magee-Women's Research Inst. & Foundation
Funding:
- Nat. Institute Allergy & Infect. Diseases (NIAID)
Funding Mechanism:
NIAID: R61
Active Ingredient(s):
- 4'-Ethynyl-2-fluoro-2'-deoxyadenosine prodrug (EFdA-P)
- Progestin
Product Indication(s):
- HIV
- Pregnancy